Trial Profile
A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs IRX 2 (Primary) ; Cyclophosphamide; Indometacin; Multivitamin; Omeprazole; Zinc
- Indications Head and neck cancer; Mouth neoplasm; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms INSPIRE
- Sponsors Eterna Therapeutics; IRX Therapeutics
- 07 May 2023 Status changed from active, no longer recruiting to completed.
- 26 Jul 2022 According to a Brooklyn ImmunoTherapeutics media release, the company expects to present he results of the INSPIRE study at a scientific conference later this year.
- 26 Jul 2022 Results presented in the Brooklyn ImmunoTherapeutics Media Release.